Literature DB >> 24371774

The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidine.

Omar Al Ustwani1, Jessica D Greene2, Meir Wetzler1.   

Abstract

Patients with myelodysplastic syndrome who fail hypomethylating agents have a very short median survival and about 25% risk of disease transformation to acute myeloid leukemia. We report our experience with low-dose protracted oral clofarabine in one patient who achieved stable disease for more than two years after failing 5-azacitidine.

Entities:  

Keywords:  Azacitidine; Clofarabine; Decitabine; Myelodysplastic syndrome

Year:  2013        PMID： 24371774      PMCID： PMC3850391          DOI： 10.1016/j.lrr.2013.03.002

Source DB:  PubMed          Journal:  Leuk Res Rep        ISSN： 2213-0489


  6 in total

1.  A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.

Authors:  Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Gautam Borthakur; Zeev Estrov; Varsha Gandhi; Anna L Byrd; Monica Kwari; Jorge Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

2.  Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.

Authors:  Stefan Faderl; Guillermo Garcia-Manero; Zeev Estrov; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Susan O'Brien; Varsha Gandhi; William Plunkett; Anna Byrd; Monica Kwari; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

3.  Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.

Authors:  Elias Jabbour; Guillermo Garcia-Manero; Nicolas Batty; Jenny Shan; Susan O'Brien; Jorge Cortes; Farhad Ravandi; Jean-Pierre Issa; Hagop Kantarjian
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

4.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Thomas Prébet; Steven D Gore; Benjamin Esterni; Claude Gardin; Raphael Itzykson; Sylvain Thepot; François Dreyfus; Odile Beyne Rauzy; Christian Recher; Lionel Adès; Bruno Quesnel; C L Beach; Pierre Fenaux; Norbert Vey
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

5.  Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

Authors:  Hagop Kantarjian; Pierre Fenaux; Mikkael A Sekeres; Pamela S Becker; Adam Boruchov; David Bowen; Eva Hellstrom-Lindberg; Richard A Larson; Roger M Lyons; Petra Muus; Jamile Shammo; Robert Siegel; Kuolung Hu; Janet Franklin; Dietmar P Berger
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

6.  Myelodysplastic syndromes: incidence and survival in the United States.

Authors:  Xiaomei Ma; Monique Does; Azra Raza; Susan T Mayne
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.